Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 333Neoplasms 221Prostatic Neoplasms 197Carcinoma, Non-Small-Cell Lung 156Lung Neoplasms 135Pancreatic Neoplasms 118Colorectal Neoplasms 103Neoplasm Metastasis 100Carcinoma, Hepatocellular 96Leukemia, Myeloid, Acute 94Multiple Myeloma 91Brain Neoplasms 89Lymphoma 86Head and Neck Neoplasms 76Melanoma 73Ovarian Neoplasms 72Leukemia 71Leukemia, Lymphocytic, Chronic, B-Cell 69Glioblastoma 69Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Colonic Neoplasms 61Recurrence 59Lymphoma, Non-Hodgkin 54Rectal Neoplasms 50Hematologic Neoplasms 50Lymphoma, Follicular 49Glioma 49Squamous Cell Carcinoma of Head and Neck 47Lymphoma, Large B-Cell, Diffuse 47Carcinoma, Renal Cell 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × OTHER × EBV Lymphomas × Clear all
NCT03988582 2020-06-11

Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies

Memorial Sloan Kettering Cancer Center

Phase 2 Withdrawn
Lymphoid

EBV Lymphomas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡